The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Trinity Biotech's share price is €2.12.
Trinity Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was €8.75. Hence, Trinity Biotech's PS Ratio for today is 0.24.
Good Sign:
Trinity Biotech PLC stock PS Ratio (=0.2) is close to 10-year low of 0.19
The historical rank and industry rank for Trinity Biotech's PS Ratio or its related term are showing as below:
FRA:TRB'
s PS Ratio Range Over the Past 10 Years
Min: 0.19 Med: 1.11 Max: 7.14
Current: 0.2
During the past 13 years, Trinity Biotech's highest PS Ratio was 7.14. The lowest was 0.19. And the median was 1.11.
FRA:TRB's PS Ratio is ranked better than 96.86% of 223
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.93
vs FRA:TRB: 0.20
Trinity Biotech PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Trinity Biotech was -23.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -14.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -4.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -1.50% per year.
During the past 13 years, Trinity Biotech's highest 3-Year average Revenue per Share Growth Rate was 79.40% per year. The lowest was -30.90% per year. And the median was 0.55% per year.
Back to Basics: PS Ratio
Trinity Biotech PS Ratio Historical Data
The historical data trend for Trinity Biotech's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Trinity Biotech's PS Ratio
For the Diagnostics & Research subindustry, Trinity Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech's PS Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's PS Ratio distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's PS Ratio falls into.
Trinity Biotech PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Trinity Biotech's Share Price of today is €2.12. Trinity Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.75.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Trinity Biotech PS Ratio Related Terms
Thank you for viewing the detailed overview of Trinity Biotech's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:TRB has been successfully added to your 